Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. (NASDAQ: AEMD) is a clinical-stage medical device innovator advancing the Hemopurifier® - a therapeutic filtration device targeting cancer-enabling exosomes and life-threatening viruses. This page provides investors and medical professionals with essential updates on clinical developments, regulatory progress, and strategic initiatives.
Key resources include press releases detailing trial protocols, ethics committee approvals, and operational milestones. Users will find verified information on oncology applications for treatment-resistant cancers and infectious disease programs, all presented in compliance with financial disclosure standards.
Content highlights encompass FDA communications, trial enrollment updates, and peer-reviewed research collaborations. The curated news collection serves as a reliable reference for tracking the Hemopurifier®'s progress through clinical validation stages and potential therapeutic applications.
Bookmark this page for direct access to Aethlon Medical's official announcements, including breakthrough device designations and international trial expansions. Check regularly for updates on this pioneering approach to blood filtration technology and its implications for cancer immunotherapy advancement.
Investorideas.com has released a two-part series on virus treatment developments, featuring Aethlon Medical's (NASDAQ: AEMD) Hemopurifier®. The Hemopurifier® is a breakthrough device for cancer and viral disease treatment, recognized by the FDA. Recent updates include phase 1 clinical trials for cancer patients who are unresponsive to anti-PD-1 therapy. The device has shown potential in treating various viruses in vitro, including HIV, Ebola, and H5N1 bird flu. Zacks reported rising vaccine stocks due to growing bird flu threats. Other companies like ImmunityBio and Aligos Therapeutics are also advancing in viral treatments. This news follows WHO's alert on a new H5N2 bird flu strain causing a human death in Mexico.
Investorideas.com highlights advancements in blood purification medical devices, focusing on Aethlon Medical's (NASDAQ: AEMD) Hemopurifier®. The global blood purification market is projected to grow from USD 17.8 billion in 2021 to USD 29.2 billion by 2030. Aethlon plans Phase 1 trials in Australia and India for patients with stable or progressive solid tumors not responding to anti-PD-1 therapies. The Hemopurifier® aims to remove cancer-promoting exosomes and viruses. The FDA has designated it a 'Breakthrough Device' for specific cancers and viral infections. Data from recent in vitro studies support its efficacy in removing extracellular vesicles from cancer patient plasma, facilitating further clinical trials.
Aethlon Medical is advancing its phase 1 clinical trials for the Hemopurifier®, aimed at patients with solid tumors unresponsive to anti-PD-1 treatments like Keytruda® or Opdivo®.
Progress includes the integration of new in vitro data showing exosome removal from cancer patient plasma, which has been included in documentation for Ethics Committees. Submissions have been made to Ethics Boards in Australia and India, with one site already submitting on May 24, 2024.
Once approvals are received, Clinical Trial Agreements will be finalized, and patient recruitment can begin. The trials focus on safety, feasibility, and dose-finding.
Aethlon Medical (Nasdaq: AEMD), a therapeutic company specializing in cancer and infectious disease treatments, announced a public offering priced at $0.58 per share. This includes 8,100,000 common shares, Class A and Class B warrants to purchase up to 8,100,000 shares each. The Class A warrants expire in five years and Class B in one year. Gross proceeds are expected to be $4.7 million before expenses, with funds directed towards clinical trials, R&D, capital expenditures, and working capital. Closing is anticipated by May 17, 2024. Maxim Group is the exclusive placement agent.
Aethlon Medical, Inc. reported positive results from an in vitro binding study of its Hemopurifier® in removing extracellular vesicles (EVs) from cancer patient plasma. The study supports the design of a Phase 1 trial in cancer patients with solid tumors undergoing anti-PD-1 treatment. The Hemopurifier showed promise in reducing EVs from plasma, paving the way for upcoming clinical trials in Australia and India.
FAQ
What is the current stock price of Aethlon Medical (AEMD)?
What is the market cap of Aethlon Medical (AEMD)?
